From 2000 to 2004, a total of 23,893,092 individuals, aged 18 to 65 years were enrolled in Medicaid. We identified 34,339 individuals with SLE, for an overall prevalence of 143.7 per 100,000. The prevalence of SLE among females was 6 times higher compared to males; 38.5% of individuals with SLE were African American, 13.9% Hispanic, 4.2% Asian, 1.5% Native American, and 36.2% White. The highest SLE prevalence was in the South (163.5 per 100,000) and the lowest was in the Northeast (125.2 per 100,000).
Lupus nephritis is treated with medications that suppress the immune system, so it stops attacking and damaging the kidneys. Standard treatment includes a corticosteroid, usually prednisone, to reduce inflammation in the kidneys. An immunosuppressive medication, such as cyclophosphamide or mycophenolate mofetil, is typically used with prednisone. These medications—when taken as prescribed by a health care provider—further decrease the activity of the immune system and block the body’s immune cells from attacking the kidneys directly or making antibodies that attack the kidneys.
Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) announced that a Phase III study of Rituxan® (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks. The primary endpoint evaluated improvements in kidney response as measured by standard laboratory tests used to assess kidney health. A preliminary analysis of the safety data did not reveal any new or unexpected safety signals in patients receiving Rituxan